1
Country: USA | Funding: $1B
SpringWorks Therapeutics is a biopharmaceutical company focused on developing medicines for patients with severe rare diseases and cancer.
SpringWorks Therapeutics is a biopharmaceutical company focused on developing medicines for patients with severe rare diseases and cancer.
2
Country: USA | Funding: $622M
Arcellx develops cell-based therapies for cancer treatment, based on immune cells that can be easily suppressed, activated and reprogrammed throughout the disease course. The company has developed D-domain - small, stable, fully synthetic binding protein with a hydrophobic core that serves as a chimeric antigen receptor, potentially enabling high transduction efficiency, leading to high cell surface expression of CAR T cells. Using this protein, Arcellx creates drugs (modified T cells) that bind to target cells and kill them with improved specificity and increased binding affinity. The company's lead drug, anitokabtagene autoleucel, is undergoing clinical trials for patients with relapsed or refractory multiple myeloma and acute myeloid leukemia.
Arcellx develops cell-based therapies for cancer treatment, based on immune cells that can be easily suppressed, activated and reprogrammed throughout the disease course. The company has developed D-domain - small, stable, fully synthetic binding protein with a hydrophobic core that serves as a chimeric antigen receptor, potentially enabling high transduction efficiency, leading to high cell surface expression of CAR T cells. Using this protein, Arcellx creates drugs (modified T cells) that bind to target cells and kill them with improved specificity and increased binding affinity. The company's lead drug, anitokabtagene autoleucel, is undergoing clinical trials for patients with relapsed or refractory multiple myeloma and acute myeloid leukemia.
3
Country: USA | Funding: $460.5M
Poseida Therapeutics develops differentiated allogeneic cell therapies and genetic medicines using our proprietary genetic engineering platforms. The company develops the piggyBac non-viral DNA delivery system (which enables introduction of large genetic data into the genome) and the Cas-CLOVER site-specific gene editing system (which can be used for precise site-specific deletions, insertions and knockouts in various cell types). Using this platform, the company creates CAR-T therapies with high levels of desired TSCM (stem cell-derived memory T cells) for the treatment of a range of oncological, autoimmune and rare diseases, including multiple myeloma, acute myeloid leukemia and prostate cancer. Poseida was acquired by Roche in early 2025.
Poseida Therapeutics develops differentiated allogeneic cell therapies and genetic medicines using our proprietary genetic engineering platforms. The company develops the piggyBac non-viral DNA delivery system (which enables introduction of large genetic data into the genome) and the Cas-CLOVER site-specific gene editing system (which can be used for precise site-specific deletions, insertions and knockouts in various cell types). Using this platform, the company creates CAR-T therapies with high levels of desired TSCM (stem cell-derived memory T cells) for the treatment of a range of oncological, autoimmune and rare diseases, including multiple myeloma, acute myeloid leukemia and prostate cancer. Poseida was acquired by Roche in early 2025.
4
Country: USA | Funding: $335.4M
Kite Pharma develops and produces immune-based cell therapies to treat cancer. Each cell therapy developed by the company is individually tailored to each patient and one-time injected. The CAR T-cell therapy manufacturing process involves collecting the patient's white blood cells, isolating and activating the T-cells, modifying the T-cells with a chimeric antigen receptor gene, culturing and expanding the T-cells and administering the modified T-cells to the same patient. Kite has a state-of-the-art manufacturing facility with full production cycle and global logistics network. The company's portfolio includes two drugs for the treatment of blood diseases, specifically diffuse large B-cell lymphoma, mantle cell lymphoma and acute lymphoblastic leukemia. The company's pipeline includes clinical trials for the treatment of lymphoma, myeloma and leukemia. Acquired by Gilead Sciences
Kite Pharma develops and produces immune-based cell therapies to treat cancer. Each cell therapy developed by the company is individually tailored to each patient and one-time injected. The CAR T-cell therapy manufacturing process involves collecting the patient's white blood cells, isolating and activating the T-cells, modifying the T-cells with a chimeric antigen receptor gene, culturing and expanding the T-cells and administering the modified T-cells to the same patient. Kite has a state-of-the-art manufacturing facility with full production cycle and global logistics network. The company's portfolio includes two drugs for the treatment of blood diseases, specifically diffuse large B-cell lymphoma, mantle cell lymphoma and acute lymphoblastic leukemia. The company's pipeline includes clinical trials for the treatment of lymphoma, myeloma and leukemia. Acquired by Gilead Sciences
5
Country: Australia | Funding: A$10M
HaemaLogiX develops novel immuno-oncology and immunotherapy drugs for the treatment of blood cancers and B-cell diseases. Unlike existing treatments, HaemaLogiX products preserve the patient's immune system, helping fight cancer and maintain resistance to life-threatening infections during treatment. HaemaLogiX drugs are monoclonal antibodies that bind to unused and unique targets - KMA (kappa myeloma antigen) and LMA (lambda myeloma antigen) antigens - which are absent on normal plasma cells. The company is also developing KMA.CAR-T cell therapy, designed for separate subsets of multiple myeloma patients to KappaMab who have become resistant to standard treatments. The binding arm of KappaMab is connected to two proteins inside the T cell that are capable of stimulating and signalling to the T cell that it should destroy the KMA-positive myeloma cell.
HaemaLogiX develops novel immuno-oncology and immunotherapy drugs for the treatment of blood cancers and B-cell diseases. Unlike existing treatments, HaemaLogiX products preserve the patient's immune system, helping fight cancer and maintain resistance to life-threatening infections during treatment. HaemaLogiX drugs are monoclonal antibodies that bind to unused and unique targets - KMA (kappa myeloma antigen) and LMA (lambda myeloma antigen) antigens - which are absent on normal plasma cells. The company is also developing KMA.CAR-T cell therapy, designed for separate subsets of multiple myeloma patients to KappaMab who have become resistant to standard treatments. The binding arm of KappaMab is connected to two proteins inside the T cell that are capable of stimulating and signalling to the T cell that it should destroy the KMA-positive myeloma cell.
6
Country: Israel | Funding: $415.4K
UB Therapeutics is developing new therapy for the treatment of multiple myeloma. It's candidate, proteasome degradation inhibitor, has shown great promise in early preclinical studies. It differs from other proteasome inhibitors in that it more directly targets the proteasome degradation pathway, potentially leading to increased efficacy in patients who have developed resistance to other FDA-approved proteasome inhibitors. The compound is a cyclic peptide with potential anticancer therapeutic activity, blocking the action of deubiquitinases and the proteasome, inducing apoptosis in vitro, and attenuating tumor growth in vivo. This distinct mechanism may have therapeutic advantages as it avoids the innate and acquired resistance associated with direct proteasome inhibitors.
UB Therapeutics is developing new therapy for the treatment of multiple myeloma. It's candidate, proteasome degradation inhibitor, has shown great promise in early preclinical studies. It differs from other proteasome inhibitors in that it more directly targets the proteasome degradation pathway, potentially leading to increased efficacy in patients who have developed resistance to other FDA-approved proteasome inhibitors. The compound is a cyclic peptide with potential anticancer therapeutic activity, blocking the action of deubiquitinases and the proteasome, inducing apoptosis in vitro, and attenuating tumor growth in vivo. This distinct mechanism may have therapeutic advantages as it avoids the innate and acquired resistance associated with direct proteasome inhibitors.
7
Country: Canada
Myellama Therapeutics is a preclinical company developing a family of proprietary cellular and multispecific nanoantibodies for the treatment of myeloma. These antibodies, TACI/BCMA, are naturally found in camelids such as llamas. They effectively target T cells or natural killer cells to malignant plasma cells. They recognize the TACI marker on the surface of myeloma cells, rather than the more common BCMA marker. Now, patients requiring additional treatment before or after existing immunotherapy drugs, such as ciltacebtagene autoleucel, idecabtagene vicleucel, teclistimab, or elranatamab, will have more options. The company is getting ready for simultaneous Health Canada CTA and FDA NDA application with first patient enrollement anticipated in 2027
Myellama Therapeutics is a preclinical company developing a family of proprietary cellular and multispecific nanoantibodies for the treatment of myeloma. These antibodies, TACI/BCMA, are naturally found in camelids such as llamas. They effectively target T cells or natural killer cells to malignant plasma cells. They recognize the TACI marker on the surface of myeloma cells, rather than the more common BCMA marker. Now, patients requiring additional treatment before or after existing immunotherapy drugs, such as ciltacebtagene autoleucel, idecabtagene vicleucel, teclistimab, or elranatamab, will have more options. The company is getting ready for simultaneous Health Canada CTA and FDA NDA application with first patient enrollement anticipated in 2027
